Os therapies receives positive fda meeting feedback on regulatory pathway for accelerated approval of ost-her2 in the prevention or delay of recurrent, fully resected, pediatric lung metastatic osteosarcoma

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today announced that it received positive written feedback from the us food & drug administration (“fda”) type d meeting that occurred in mid-june 2025 regarding endpoints required to support an accelerated approval program marketing application for its phase 2b trial of ost-her2 in the prevention or delay of re.
OST Ratings Summary
OST Quant Ranking